Page 1

08/860,377

=> file caplus

FILE 'CAPLUS' ENTERED AT 13:02:58 ON 10 JUL 1998 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 1998 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 10 Jul 1998 VOL 129 ISS 2 FILE LAST UPDATED: 10 Jul 1998 (980710/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file now supports REG1stRY for direct browsing and searching of all non-structural data from the REGISTRY file. Enter HELP FIRST for more information.

=> d que

STR L1

Structure attributes must be viewed using STN Express query preparation.

22 SEA FILE=REGISTRY SSS FUL L1 L3

2 SEA FILE=CAPLUS L3 L4

=> d 14 1-2 ibib abs hitstr

ANSWER 1 OF 2 CAPLUS COPYRIGHT 1998 ACS ACCESSION NUMBER: 1998:35996 CAPLUS

128:114881 DOCUMENT NUMBER:

Preparation of quinuclidine-containing TITLE:

isoquinolines and muscarine M3 receptor

antagonists containing them

Naito, Ryo; Takeuchi, Makoto; Okamoto, INVENTOR(S):

Yoshinori; Ikeda, Masaru; Isomura, Yasuo Yamanouchi Pharmaceutical Co., Ltd., Japan

PATENT ASSIGNEE(S): Jpn. Kokai Tokkyo Koho, 11 pp. SOURCE:

CODEN: JKXXAF

DATE NUMBER

JP 10007675 A2 980113 Heisei PATENT INFORMATION:

APPLICATION INFORMATION: JP 96-162221 960621 DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

OTHER SOURCE(S):

MARPAT 128:114881

GI

$$(R^3)$$
 m (O) n (O) n (R^3) m (O) m (O) n (O) n

AB Isoquinolines I (R1 = OH, lower alkoxy, lower alkyl; R2 = aryl, cycloalkyl, heterocyclyl; R3 = halo, OH, lower alkoxy, CO2H, lower alkoxycarbonyl, lower acyl, etc.; m = 0-3; n = 0, 1) or their salts, useful as muscarine M3 receptor antagonists, are prepd.

(.+-.)-Trans-1-phenyl-1,2,3,4-tetrahydro-4-isoquinolinol (0.28 g) was treated with 0.28 g (3R)-3-quinuclidinyl chloroformate.HCl at room temp. for 2.5 h to give 0.15 g trans-(1S,3'R,4S)- and trans-(1R,3'R,4R)-I (R1 = OH, R2 = Ph, R3 = H, n = 0). I was tested for in vitro muscarine receptor affinity and in vivo antagonistic activity.

IT 201660-36-8P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of quinuclidine-contg. isoquinolines as muscarine M3 receptor antagonists)

RN 201660-36-8 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-4-hydroxy-1-phenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester, [2(R)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 1998 ACS

ACCESSION NUMBER:

1996:516723 CAPLUS

DOCUMENT NUMBER:

125:167804

TITLE:

Preparation of new quinuclidine derivatives as muscarinic M3 receptor antagonists

INVENTOR(S):

Takeuchi, Makoto; Naito, Ryo; Hayakawa, Masahiko; Okamoto, Yoshinori; Yonetoku, Yasuhiro; Ikeda, Ken; Isomura, Yasuo

PATENT ASSIGNEE(S):

Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE:

PCT Int. Appl., 75 pp.

CODEN: PIXXD2

NUMBER DATE
----WO 9620194 A1 960704

PATENT INFORMATION: DESIGNATED STATES:

WO 9620194 A1 960704

W: AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN

RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK,

RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE,

NL, PT, SE, SN, TD, TG

APPLICATION INFORMATION: WO 95-JP2713 PRIORITY APPLN. INFO.: JP 94-327045

WO 95-JP2713 951227 JP 94-327045 941228

DOCUMENT TYPE:

Patent Japanese

LANGUAGE:
OTHER SOURCE(S):

MARPAT 125:167804

Ι

GΙ

IT

$$R_{m} \xrightarrow{\text{(CH2)}_{n}} N$$

$$X$$

$$CO - O - O$$

Ouinuclidine derivs. I [ring A = optionally substituted aryl, AB cycloalkyl, cycloalkenyl, heteroaryl contg. 1 to 4 heteroatoms selected from among oxygen, nitrogen and sulfur, or 5- to 7-membered satd. heterocycle; X = single bond or methylene; R = halo, hydroxy, lower alkoxy, carboxy, lower alkoxycarbonyl, lower acyl, mercapto, lower alkylthio, sulfonyl, lower alkylsulfonyl, sulfinyl, lower alkylsulfinyl, sulfonamido, lower alkanesulfonamido, carbamoyl, thio-carbamoyl, mono- or di(lower alkyl)carbamoyl, nitro, cyano, amino, mono- or di(lower alkyl)amino, methylenedioxy, ethylenedioxy or lower alkyl optionally substituted by halogeno, hydroxy, lower alkoxy, amino or mono- or di(lower alkyl) amino; p = 0 or 1; m = 1 integer of 1 to 3; n = 1 integer of 1 or 2], their salts, N-oxides, or quaternary ammonium salts, having an antagonistic effect on muscarinic M3 receptors and are useful as a preventive or remedy for urol. diseases, respiratory diseases or digestive diseases, are prepd. Thus, Et 1-phenyl-1,2,3,4-tetrahydro-2isoquinolinecarboxylate (prepn. given) was reacted with 3-quinuclidinol in toluene contg. NaH at 140.degree. for 2 days to give the title compd. 3-quinuclidinyl 1-phenyl-1,2,3,4-tetrahydro-2isoquinolinecarboxylate isolated as the oxalate salt. In an in vitro study, I had Ki values of 10-3 to 10-10 M against muscarinic M3 receptors.

180272-14-4P 180272-15-5P 180272-16-6P

180272-17-7P 180272-19-9P 180272-20-2P 180272-21-3P 180272-23-5P 180272-24-6P 180272-25-7P 180272-26-8P 180272-27-9P 180272-28-0P 180272-29-1P 180272-30-4P 180468-37-5P 180468-38-6P 180468-39-7P 180468-40-0P RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of new quinuclidine derivs. as muscarinic M3 receptor antagonists) RN 180272-14-4 CAPLUS 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, CN 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

RN 180272-15-5 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
1-azabicyclo[2.2.2]oct-3-yl ester, ethanedioate (1:1) (9CI) (CA
INDEX NAME)

CM 1

CRN 180272-14-4 CMF C23 H26 N2 O2

CM 2

CRN 144-62-7 CMF C2 H2 O4

RN 180272-16-6 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA

INDEX NAME)

● HCl

RN 180272-17-7 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-(4-pyridinyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, dihydrochloride (9CI) (CA INDEX NAME)

●2 HCl

RN 180272-19-9 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-(2-thienyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180272-18-8 CMF C21 H24 N2 O2 S

Page 6

CM 2

CRN 144-62-7 CMF C2 H2 O4

RN 180272-20-2 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-(3-thienyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

RN 180272-21-3 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 1-(2-furanyl)-3,4-dihydro-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

RN 180272-23-5 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 1-(4-chlorophenyl)-3,4-dihydro-, 1-azabicyclo[2.2.2]oct-3-yl ester, (E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180272-22-4 CMF C23 H25 C1 N2 O2

CM 2

CRN 110-17-8 CMF C4 H4 O4 CDES 2:E

Double bond geometry as shown.

RN 180272-24-6 CAPLUS CN 2(1H)-Isoquinolinecarboxylic acid, 1-(4-fluorophenyl)-3,4-dihydro-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

RN 180272-25-7 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-(4-methylphenyl)-,
1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

RN 180272-26-8 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-(phenylmethyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

RN 180272-27-9 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 1-cyclohexyl-3,4-dihydro-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

RN 180272-28-0 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, 1-oxido-1-azabicyclo[2.2.2]oct-3-yl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.


• I-

RN 180272-30-4 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 1-(3-furanyl)-3,4-dihydro-,
1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

RN 180468-37-5 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride, [R-(R*,R*)](9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Page 10



HCl

RN 180468-38-6 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride, [S-(R*,R*)](9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

HCl

RN 180468-39-7 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride, [R-(R*,S*)] (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

● HCl

RN 180468-40-0 CAPLUS CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride, $[S-(R^*,S^*)]-(9CI)$ (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

● HCl

=> file caold

FILE 'CAOLD' ENTERED AT 13:04:08 ON 10 JUL 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1998 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1957-1966 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

=> d que

Structure attributes must be viewed using STN Express query preparation.

L3 22 SEA FILE=REGISTRY SSS FUL L1

L6 0 SEA FILE=CAOLD L3